Abstract
N-valproyl-l-tryptophan (VPA-Tryp), new antiepileptic drug, was tested on CA1 hippocampal epileptiform bursting activity obtained by increasing potassium and lowering calcium and magnesium concentrations in the fluid perfusing rat brain slices. Each slice was treated with a single concentration (0.2, 0.5, 1 or 2 mM) of Valproate (VPA) or VPA-Tryp. Both burst duration and interburst frequency during and after treatment were off-line compared with baseline values. For both parameters, the latency and the length of statistically significant response periods as well as the magnitude of drug-induced responses were calculated. VPA-Tryp evoked fewer and weaker early excitatory effects than VPA on bursting activity. On the contrary, VPA-Tryp induced powerful and long-lasting inhibitory effects on epileptiform discharge in a significantly higher number of slices than VPA. In fact, greater length and magnitude of VPA-Tryp-induced inhibition on both interburst frequency and burst duration were observed. Furthermore, VPA-Tryp showed antiepileptic activity at lower concentration than VPA and, when testing both drugs at analogue concentrations, VPA-Tryp evoked responses with either shorter latency or greater effect length and magnitude than VPA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armand V, Louvel J, Pumain R, Heinemann U (1998) Effects of new valproate derivatives on epileptiform discharges induced by pentylenetetrazole or low Mg2+ in rat entorhinal cortex-hippocampus slices. Epilepsy Res 32:345–355
Baillie TA, Sheffels PR (1995) Valproic acid, chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic drugs, 4th edn. Raven Press, New York, pp 589–603
Bauer J (1996) Seizure-inducing effects of antiepileptic drugs: a review. Acta Neurol Scand 94:367–377
Bialer M, Yagen B (2007) Valproic acid: second generation. Neurotherapeutics 4:130–137
Chapman A, Keane PE, Meldrum BS, Simiand J, Verniers JC (1982) Mechanisms of anticonvulsant action of valproate. Prog Neurobiol 19:315–359
Davies JA (1995) Mechanisms of action of antiepileptic drugs. Seizure 4:267–271
De Caro V, Giandalia G, Siragusa MG, Lamartina L, Friscia S, Sardo P, Carletti F, Rizzo V, Ferraro G, Giannola LI (2011) N-Valproyl-l-Tryptophan for CNS-targeting: synthesis, sharacterization and sfficacy in vitro studies of a new potential antiepileptic drug. Med Chem 7:9–17
Einat H, Tian F, Belmaker RH, Frost JW (2008) Myo-inositol-1-phosphate (MIP) synthase inhibition: in vivo study in rats. J Neural Transm 115(1):55–58
Giannola LI, Lamartina L, De Caro V (1998) Synthesis and characterization of aminoacidic pro-drugs of valproic acid. Pharmazie 53:829–834
Isoherranen N, Yagen B, Spiegelstein O, Finnell RH, Merriweather M, Woodhead JH, Wlodarczyk B, White HS, Bialer M (2003) Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice. Br J Pharmacol 139:755–764
Jefferys JG, Haas HL (1982) Synchronized bursting of CA1 hippocampal pyramidal cells in the absence of synaptic transmission. Nature 300:448–450
Keane PE, Simiand J, Mendes E, Santucci V, Morre M (1983) The effects of analogues of valproic acid on seizures induced by pentylenetetrazol and GABA content in brain of mice. Neuropharmacology 22:875–879
Leschinger A, Stabel J, Igelmund P, Heinemann U (1993) Pharmacological and electrographic properties of epileptiform activity induced by elevated K+ and lowered Ca2+ and Mg2+ concentration in rat hippocampal slices. Exp Brain Res 96:230–240
Löscher W (2002) Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16:669–694
Nagai G, Ono S, Yasui-Furukori N, Nakamura A, Mihara K, Kondo T (2009) Formulations of valproate alter valproate metabolism: a single oral dose kinetic study. Ther Drug Monit 31:592–596
Peterson GM, Naunton M (2005) Valproate: a simple chemical with so much to offer. J Clin Pharm Ther 30:417–421
Semmes RL, Shen DD (1991) Comparative pharmacodynamics and brain distribution of E-delta 2-valproate and valproate in rats. Epilepsia 32:232–241
Smith KA, Bierkamper GG (1990) Paradoxical role of GABA in a chronic model of petit mal (absence)-like epilepsy in the rat. Eur J Pharmacol 176:45–55
Sokolova S, Schmitz D, Zhang CL, Löscher W, Heinemann U (1998) Comparison of effects of valproate and trans-2-en-valproate on different forms of epileptiform activity in rat hippocampal and temporal cortex slices. Epilepsia 39:251–258
Trojnar MK, Weirzchowska-Cioch E, Krzyzanowski M, Jargiello M, Czuzczwar SJ (2004) New generation of valproic acid. Pol J Pharmacol 56:283–288
Acknowledgments
The research was founded by Università di Palermo, Programma di Ricerca Innovativo, Prot. IIPA073ER4, 2007.
Conflict of interest
The authors declare they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sardo, P., Rizzo, V., Friscia, S. et al. Inhibitory effects of N-valproyl-l-tryptophan on high potassium, low calcium and low magnesium-induced CA1 hippocampal epileptiform bursting activity in rat brain slices. J Neural Transm 119, 1249–1259 (2012). https://doi.org/10.1007/s00702-012-0814-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-012-0814-y